Bullish
Vertex Reports First Quarter 2026 Financial Results
Vertex Pharmaceuticals reported consolidated financial results for the first quarter of 2026, with total revenue increasing 8% to $2.99 billion compar...
VRTX
--
--
--
--
Price Chart (30 Days)
Ad Space
Analyst Sentiment
Bullish (9)
Neutral (3)
Bearish (0)
Latest VRTX News
Bullish
Bullish
Earnings call transcript: Vertex Pharmaceuticals Q1 2026 performance review
Vertex Pharmaceuticals reported Q1 2026 earnings, exceeding EPS forecasts with $4.47 but missing revenue projections at $2.99 billion. The company hig...
Bullish
(VRTX) Vertex Pharmaceuticals Expects 2026 Revenue Range $12.95B-$13.1B, vs. FactSet Est of $13.05B
Vertex Pharmaceuticals (VRTX) anticipates its 2026 revenue to fall between $12.95 billion and $13.1 billion. This forecast is in line with FactSet's e...
Bullish
Vertex Reports First Quarter 2026 Financial Results
Vertex Pharmaceuticals reported strong Q1 2026 financial results, with total revenue increasing 8% to $2.99 billion, driven by continued growth in cys...
Vertex Pharmaceuticals (VRTX) Q1 Earnings: What To Expect
Vertex Pharmaceuticals (VRTX) is set to report its Q1 earnings, with analysts expecting a 6.5% year-on-year revenue growth. The company previously bea...
Bullish
Vertex Pharmaceuticals (VRTX) Q1 Earnings: What To Expect
Vertex Pharmaceuticals (VRTX) is set to release its Q1 earnings report this Monday, with analysts anticipating a 6.5% year-on-year revenue growth. The...
Bullish
Assessing Vertex Pharmaceuticals (VRTX) Valuation After ALYFTREK Expansion And Supportive Bank Of America Commentary
Vertex Pharmaceuticals (VRTX) is gaining attention after the FDA approved expanded use of ALYFTREK for cystic fibrosis patients and Bank of America pr...
Neutral
How Cautious Earnings Sentiment Ahead of Q1 Results Will Impact Vertex Pharmaceuticals (VRTX) Investors
Vertex Pharmaceuticals (VRTX) is approaching its Q1 earnings release with expectations of increased revenue and year-over-year earnings growth. Howeve...
Neutral
Vertex Pharma stock (US92532F1003): Is the cystic fibrosis dominance now unlocking broader upside?
Vertex Pharmaceuticals dominates the cystic fibrosis market, and this report explores whether its expansion into gene editing and pain management can ...
Bullish
Morgan Stanley Lifts Vertex Pharmaceuticals (VRTX) PT on Updated Biopharma Models
Morgan Stanley has raised its price target for Vertex Pharmaceuticals (VRTX) to $612 from $596, maintaining an Overweight rating. This decision follow...
Bullish
Lightning Round: Buy Vertex Pharmaceuticals
Jim Cramer, host of "Mad Money," recommends buying Vertex Pharmaceuticals. He also provided his views on Oddity Tech, ImmunityBio, Aehr Test Systems, ...
Neutral
Vertex Pharma stock (US92532F1003): Is cystic fibrosis dominance still enough for long-term upside?
Vertex Pharmaceuticals dominates the cystic fibrosis (CF) market, but faces patent expirations in the late 2030s. The company is diversifying its pipe...
Research VRTX on:
Ad Space